Metabolic

Featured Article

Dyslipidemia and Atherosclerosis Clinical Practice Guidelines

Dyslipidemia and Atherosclerosis Clinical Practice Guidelines

New guidelines for dyslipidemia management and atherosclerosis prevention include a wider range of disease stages and more aggressive intervention.

Latest Features

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Physical Activity for Diabetes: ADA Updated Guidelines

Physical Activity for Diabetes: ADA Updated Guidelines

Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.

Hope for Heart Failure in Thyroid Hormone Therapy

Hope for Heart Failure in Thyroid Hormone Therapy

Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

PCSK9 Inhibitor Alirocumab Associated With 75% Reduction in Apheresis

Among patients with heterozygous familial hypercholesterolemia, alirocumab was associated with a 75% reduction in lipoprotein apheresis compared with placebo.

Reducing the Progression of Coronary Heart Disease With Estradiol

Reducing the Progression of Coronary Heart Disease With Estradiol

In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Higher Vitamin D Levels May Related to Higher Total Cholesterol, HDL-C

Vitamin D may influence cardiovascular disease risk via its effect on lipid levels.

Cardiovascular Safety of Naltrexone Plus Bupropion Obesity Treatment Uncertain

Cardiovascular Safety of Naltrexone Plus Bupropion Obesity Treatment Uncertain

Findings from the LIGHT trial did not establish the prespecified margin of noninferiority, defined as a hazard ratio of 1.4, after unplanned early termination.

Considering Cardiovascular Risks of Antidiabetic Drugs

Considering Cardiovascular Risks of Antidiabetic Drugs

A review of current antidiabetic drug treatments available and their individual cardiovascular risk profiles.

Latest News

Glucose Levels May Affect Functional Outcomes After Endovascular Thrombectomy

Glucose Levels May Affect Functional Outcomes After Endovascular Thrombectomy

The effect of hypoglycemia on functional outcomes after endovascular thrombectomy differs, depending on collateral status.

Cardiovascular Disease Risk Increases With Body Weight Fluctuations

Cardiovascular Disease Risk Increases With Body Weight Fluctuations

Increases in body weight fluctuations were associated with greater risk for coronary and cardiovascular events and death.

Cardiometabolic Comorbidities Found in Majority of Inpatients With Schizophrenia, Bipolar Disorder

Cardiometabolic Comorbidities Found in Majority of Inpatients With Schizophrenia, Bipolar Disorder

Study results emphasize the importance of identifying optimal treatment regimens for patients with serious mental illness.

Sacubitril/Valsartan Improves Glycemic Control in Comorbid Heart Failure and Diabetes

Sacubitril/Valsartan Improves Glycemic Control in Comorbid Heart Failure and Diabetes

HbA1c decreased by 0.16% in the enalapril group vs 0.26% in the sacubitril/valsartan group.

Higher BMI Linked With Lower Mortality in Adult Congenital Heart Disease

Higher BMI Linked With Lower Mortality in Adult Congenital Heart Disease

Higher BMI was associated with lower all-cause and cardiac mortality in adults with congenital heart disease, even after adjusting for age, defect complexity, cyanosis, and objective exercise capacity.

Can Vitamin D Improve Statin Efficacy in Patients With HIV?

Can Vitamin D Improve Statin Efficacy in Patients With HIV?

While patients taking rosuvastatin did not see an increase in 25(OH)D levels, baseline vitamin D deficiency decreased rouvastatin's effectiveness.

Safety of Extremely Low LDL Cholesterol Levels

Safety of Extremely Low LDL Cholesterol Levels

Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.

Enteric-Coated Aspirin Therapy in Type 2 Diabetes and Obesity

Enteric-Coated Aspirin Therapy in Type 2 Diabetes and Obesity

Patients with obesity and type 2 diabetes were exposed to 3 different aspirin formulations.

FDA: Empagliflozin Can Reduce Risk for Cardiovascular Death

FDA: Empagliflozin Can Reduce Risk for Cardiovascular Death

In a postmarket trial of more than 7000 adults, empagliflozin was superior to placebo for reduction of cardiovascular death.

Disparity in Dyslipidemia Testing in HIV

Disparity in Dyslipidemia Testing in HIV

Women and African Americans are often under-tested for dyslipidemia, resulting in elevated risks for cardiovascular disease.

Sign Up for Free e-Newsletters